Position in ADCT
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$891,135
+$161,924 QoQ
Shares Held
237,637
+15.0% QoQ
Ownership
0.187%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ADCT Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026AQR CAPITAL MANAGEMENT LLC holds $1,491,893,072 across 43 Drug Manufacturers - Specialty & Generic names. ADCT ranks #35 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
|
4,938,967 | $650,659,508 | |
| 2 | UTHR |
UNITED THERAPEUTICS Corp
|
826,226 | $489,935,489 | |
| 3 | VTRS |
Viatris Inc
|
6,341,318 | $85,671,200 | |
| 4 | ZTS |
Zoetis Inc.
|
607,950 | $71,865,765 | |
| 5 | IRWD |
Ironwood Pharmaceuticals Inc
|
7,535,080 | $26,448,126 | |
| 6 | KNSA |
Kiniksa Pharmaceuticals International, plc
|
378,697 | $18,234,258 | |
| 7 | TAK |
Takeda Pharmaceutical Co Ltd
|
894,423 | $16,564,712 | |
| 8 | ALKS |
Alkermes plc.
|
383,977 | $13,577,424 |
All Filings in ADCT
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $891,135 | 237,637 | Shares | Other | 2026-05-15 | |
| 2025-12-31 | $729,211 | 206,576 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | $581,008 | 145,252 | Shares | Other | 2025-11-14 | |
| 2025-06-30 | $376,752 | 140,580 | Shares | Other | 2025-08-14 | |
| 2025-03-31 | $283,646 | 201,170 | Shares | Other | 2025-05-15 | |
| 2024-12-31 | $78,329 | 39,362 | Shares | Defined | 2025-02-14 | |
| 2024-09-30 | $69,636 | 22,107 | Shares | Other | 2024-11-14 | |
| No filing history on record for this holder in this stock. | ||||||